- Home
- Healthcare
-
Cardiac Biomarkers Market
Cardiac Biomarkers Market by Product Type (Myoglobin, Troponins, Brain Natriuretic Peptide or NT-proBNP, Ischemia-modified Albumin, Myocardial Muscle Creatine Kinase and Others), Application (Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Myocardial Infarction and Others), Location of Testing (Point of Care Testing and Laboratory Testing), And Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits - Forecast 2023-2030
Industry : Healthcare | Pages : 194 Pages | Published On : Jul 2024
Market Overview
Cardiac markers or cardiac biomarkers these are the substances released into the bloodstream when the heart is stressed or its muscles are injured. These markers include various enzymes, hormones and proteins like cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Testing these markers helps diagnose heart conditions such as cardiac ischemia and acute coronary syndrome (ACS). Currently, triage and diagnostic systems rely on electrocardiograms (ECGs) and medical history, which may not always provide accurate results and could lead to misdiagnosis or treatment delays. Cardiac marker testing is gaining popularity worldwide because it provides greater precision in detecting these conditions early. These markers also assist in monitoring the prognosis of these conditions more accurately and ensuring the best possible treatment for patients. Healthcare providers are concentrating on finding these particular markers to identify and diagnose serious heart conditions such as acute coronary syndrome (ACS) and heart attacks. The increasing use of cardiac biomarkers in comprehensive diagnostics for various cardiovascular diseases such as ischemia modified albumin (IMA), myoglobin, troponin I and T, brain natriuretic peptide (BNP), myocardial muscle creatine kinase, and others is creating greater demand for these tests. As heart disease becoming more common there will likely be a greater need for cardiac markers. As more people are diagnosed with heart problems due to factors like high blood pressure, high cholesterol, obesity, smoking and lack of exercise, there will be an increased demand for tests and biomarkers to help identify, evaluate and treat these conditions. As awareness grows about these risk factors, people are more interested in keeping track of their heart health.
Cardiac Biomarkers Market Size
Report | Details |
---|---|
Market Size Value | USD 15.10 Billion in 2023 |
Market Size Value | USD 36.30 Billion by 2030 |
CAGR | 13.3% |
Forecast Period | 2023-2030 |
Base Year | 2023 |
Historic Data | 2020 |
Major vendors in the global Cardiac biomarkers market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Bio-Rad Laboratories, Ortho Clinical Diagnostics, Randox Laboratories, Quidel Corporation, Radiometer, Tosoh Corporation, Meso Scale Diagnostics (MSD), Thermo Fisher Scientific, Luminex Corporation, Trinity Biotech, Biomerieux and Others.
Increasing incidence of cardiovascular diseases
The increasing number of people affected by cardiovascular diseases is a major driver of growth in the cardiac biomarkers market. These diseases are now among the top causes of death globally, with over 17 million deaths each year and is projected to rise to over 23.6 million by 2030, according to the World Health Organization. Factors contributing to this rise include aging populations, more sedentary lifestyles, unhealthy diets, increased stress levels, smoking, and higher rates of obesity and diabetes. Given the significant impact of cardiovascular diseases on public health and economies, there is now a heightened focus on early detection, diagnosis, and management. Cardiac biomarkers have emerged as critical tools for healthcare providers which is helping them confirm or rule out heart attacks and assess patients with symptoms of acute coronary syndrome. This widespread use of biomarkers in clinical settings is driving market growth. For instance, data from the British Heart Foundation in January 2022 highlighted widespread heart conditions globally in 2021 which is including coronary heart disease affecting 200 million people, peripheral arterial disease affecting 110 million, stroke affecting 100 million and atrial fibrillation affecting 60 million. These conditions vary regionally, with North America, Europe, Africa, South America, and Asia/Australia reporting varying prevalence rates. With the continuous rise in these conditions the demand for early detection and effective treatment is expected to expand which is further shaping the market's growth trajectory in the coming years.
Market Dynamics
Drivers:
- Increasing incidence of cardiovascular diseases
- Growing geriatric population
- Increased awareness of early disease detection
Opportunities:
- Increasing healthcare expenditure
- Advancement in new cardiac biomarkers
- Increasing focus on personalized medicine
Advancement in new cardiac biomarkers
Advancements in new cardiac biomarkers are poised to change the field of cardiovascular medicine by providing more precise and early detection capabilities compared to traditional markers such as Troponin and CK-MB. These novel biomarkers have the potential to predict heart conditions before symptoms manifest which enable timely intervention and potentially preventing severe outcomes such as heart attacks and heart failure exacerbations. Recent studies have identified biomarkers such as ST2 and Galectin-3 as promising indicators that can forecast cardiovascular events days in advance. Compare to existing markers that primarily indicate cardiac injury after symptoms occur, these newer biomarkers provide proactive insights into the underlying biological processes associated with heart disease progression. The development of predictive biomarkers is crucial as cardiovascular diseases remain the leading cause of global mortality, especially among younger populations. By providing early warning signs, these biomarkers could transform clinical practices which allows healthcare providers to implement targeted therapies and life interventions earlier in the disease course which is ultimately improving patient outcomes and reducing healthcare costs associated with emergency treatments and hospitalizations. Continued research and validation of these biomarkers are essential to fully realize their potential in enhancing cardiovascular disease management worldwide. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally which is about 17.9 million lives annually, with a significant number occurring prematurely in people under 70 years old.
The market for cardiac biomarkers market is dominated by North America.
By analysing the cardiac biomarkers market globally across various country like North America, Europe, Asia-Pacific, and LAMEA in which North America holds the largest market share during the forecast period, driven by well-established healthcare systems and the widespread use of cardiac biomarkers for diagnosing and predicting heart conditions. The growing elderly population needs biomarker tests to detect diseases such as acute myocardial infarction which is driving the demand for these tests. Furthermore, the higher risk of cardiovascular disease and increased strain on the healthcare system is boosting the cardiac biomarkers market. Additionally, the presence of major key players in North America further fuels the market's growth in the region.
The Asia-Pacific region is projected to grow the fastest in the global cardiac biomarkers market during the forecast period. This growth is fuelled by advanced cardiac diagnostics becoming more affordable, modernization of countries and rising disposable incomes. The increasing prevalence of cardiovascular diseases (CVDs) in the region is boosting the demand for advanced diagnostics. Government support for disease-specific research and higher healthcare spending is also contributing to the growth. India, in particular, has a higher rate of cardiovascular diseases compared to other emerging countries. These factors are driving the expansion of the global cardiac biomarkers market.
The troponin segment is anticipated to hold the largest market share during the forecast period
The global market is categorized by product type into myoglobin, troponins, brain natriuretic peptide or NT-proBNP, ischemia-modified albumin, myocardial muscle creatine kinase and others in which troponin segment held the largest market share. This growth is driven by high efficiency, specificity and accurate predictive detection of cardiac events provided by these tests compared to others. The increasing cases of heart attacks and strokes worldwide also contribute to market expansion. For instance, in July 2023, Mylab Discovery Solutions introduced the Mybox+ diagnostic device, which uses optical AI engines to deliver fast and accurate results for over 30 diseases from clinical samples. This portable device is perfect for small labs and centers which enables the testing of cardiac markers like troponin, thyroid panels (T-3, T-4, TSH), and biomarkers (CRP, D-Dimer).
The BNP and NT-proBNP segment is anticipated with the highest growth rate during the forecast period. This growth is primarily fueled by their use in detecting heart damage and stress. New companies are entering the market with these tests to make substantial profits. For instance, in June 2022, LumiraDx Limited expanded its product line with the CE Mark approval for its D-Dimer test and NT-proBNP test, which will helping in clinical decision-making.
Major segmentations are distributed as follows:
- By Product Type:
- Myoglobin
- Troponins
- Brain Natriuretic Peptide or NT-proBNP
- Ischemia-modified Albumin
- Myocardial Muscle Creatine Kinase
- Others
- By Application:
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Myocardial Infarction
- Other
- By Location of Testing:
- Point of Care Testing
- Laboratory Testing
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Rest of Latin America
- Europe
- Germany
- France
- Italy
- Spain
- U.K.
- BENELUX
- CIS & Russia
- Nordics
- Austria
- Poland
- Rest of Europe
- Asia Pacific
- North America
-
- China
- Japan
- South Korea
- India
- Thailand
- Indonesia
- Malaysia
- Vietnam
- Australia & New Zealand
- Rest of Asia Pacific
-
- Middle East & Africa
-
- Saudi Arabia
- UAE
- South Africa
- Nigeria
- Egypt
- Israel
- Turkey
- Rest of MEA
Recent Developments
- February 2024, Healthline Media UK Ltd published data from a recent study identifying six biomarkers in people with rheumatoid arthritis (RA) that are linked to artery inflammation. These biomarkers could help predict heart disease risk more accurately than current methods. The study which is published in the Journal of the American Heart Association, analyzed 109 participants and found these biomarkers to be indicators of increased cardiovascular disease risk in RA patients.
- January 2024, an international academic team led by Johns Hopkins University, the Chinese University of Hong Kong, and Lund University identified 13 biomarkers that greatly improve the prediction of cardiovascular disease risk in people with type 2 diabetes. However, type 2 diabetes doubles the risk of cardiovascular disease in which traditional risk scores are outdated and ineffective for diverse populations which makes it difficult for clinicians to identify the most at-risk individuals.
- June 2023, Roche Diagnostics Corporation announced plans to release the NT-ProBNP diagnostic biomarker in response to the rising incidence of heart failure among Type 2 Diabetes (T2D) patients in India. This biomarker will help detect heart failure and manage T2D more effectively.
Answers to Following Key Questions:
- What will be the cardiac biomarkers market ’s trends & growth rate? What analysis has been done of the prices, sales, and volume of the top producers in the cardiac biomarkers market?
- What are the main forces behind worldwide cardiac biomarkers market? Which companies dominate cardiac biomarkers market?
- Which companies dominate cardiac biomarkers market? Which business possibilities, dangers, and tactics did they embrace in the market?
- What are the global Insight Engines industry's suppliers' opportunities and dangers in cardiac biomarkers market?
- What is the Insight Engines industry's regional sales, income, and pricing analysis? In the cardiac biomarkers market, who are the distributors, traders, and resellers?
- What are the main geographic areas for various trades that are anticipated to have astounding expansion over the cardiac biomarkers market?
- What are the main geographical areas for various industries that are anticipated to observe astounding expansion for cardiac biomarkers market?
- What are the dominant revenue-generating regions for cardiac biomarkers market, as well as regional growth trends?
- By the end of the forecast period, what will the market size and growth rate be?
- What are the main cardiac biomarkers market trends that are influencing the market's expansion?
- Which key product categories dominate cardiac biomarkers market? What is cardiac biomarkers market ’s main applications?
- In the coming years, which cardiac biomarkers market technology will dominate the market?
TOC
Table and Figures
Methodology:
At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.
This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.
The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.
Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.
Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.
In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.
To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.
The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.
In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.
• Product Planning Strategy
• New Product Stratergy
• Expanded Research Scope
• Comprehensive Research
• Strategic Consulting
• Provocative and pragmatic
• Accelerate Revenue & Growth
• Evaluate the competitive landscape
• Optimize your partner network
• Analyzing industries
• Mapping trends
• Strategizing growth
• Implementing plans
Covered Key Topics
Growth Opportunities
Market Growth Drivers
Leading Market Players
Company Market Share
Market Size and Growth Rate
Market Trend and Technological
Research Assistance
We will be happy to help you find what you need. Please call us or write to us:
+1 510-730-3200 (USA Number)
Email: sales@marketdigits.com